Skip to content

Study · Non-randomized trial · n = 98 · 2022

5 results

A phase II trial of lanreotide for the prevention of postoperative pancreatic fistula.

Pillarisetty VG, Abbasi A, Park JO, Sham JG

HPB : the official journal of the International Hepato Pancreato Biliary Association21 Jul 2022Cited by 14 (Europe PMC)

PMID35953409 (opens in a new tab)DOI10.1016/j.hpb.2022.07.011 (opens in a new tab)PepBankPUB-35953409
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    After preoperative lanreotide, eight patients (8%) developed CR-POPF or intra-abdominal abscess, including one DP and seven PD patients.

    In plain wordsAfter preoperative lanreotide, eight patients developed a clinically relevant pancreatic fistula or abdominal abscess.

    Peptide
    Lanreotide
    Outcome
    Not applicableCR-POPF or intra-abdominal abscess
    Study

    n = 98

    Analysis
    Primary
    Outcome group
    Surgical Complications · Gastrointestinal
    Studied dose
    120 mg single preoperative doseAs given in this study (human).

    Measurements

    Patients with CR-POPF or intra-abdominal abscess
    8 patients
    overall cohort
    Patients with CR-POPF or intra-abdominal abscess
    8%
    overall cohort

    Source sentences

    Summary
    The primary outcome was observed in eight (8%) patients in the overall cohort, one from the DP group and seven from the PD group.
    1 context sentence
    Summary · context
    We conducted a phase II single-arm trial of a single dose of preoperative lanreotide (120 mg) in patients undergoing either pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
  2. 02HumanNon-randomized trialEfficacy outcome

    After preoperative lanreotide, biochemical leak occurred in 12 patients (12.2%).

    In plain wordsAfter preoperative lanreotide, 12 patients had a biochemical leak.

    Peptide
    Lanreotide
    Outcome
    Not applicableBiochemical leak
    Study

    n = 98

    Analysis
    Secondary
    Outcome group
    Surgical Complications · Gastrointestinal
    Studied dose
    120 mg single preoperative doseAs given in this study (human).

    Measurements

    Patients with biochemical leak
    12 patients
    overall cohort
    Patients with biochemical leak
    12.2%
    overall cohort

    Source sentences

    Summary
    Biochemical leak was detected in 12 (12.2%) patients in the overall cohort.
    1 context sentence
    Summary · context
    We conducted a phase II single-arm trial of a single dose of preoperative lanreotide (120 mg) in patients undergoing either pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
  3. 03HumanNon-randomized trialSafety outcome

    After preoperative lanreotide, 27 patients (27.5%) developed complications.

    In plain wordsAfter preoperative lanreotide, 27 patients developed complications.

    Peptide
    Lanreotide
    Outcome
    Not applicableOverall complications
    Study

    n = 98

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    120 mg single preoperative doseAs given in this study (human).

    Measurements

    Patients with complications
    27 patients
    overall cohort
    Patients with complications
    27.5%
    overall cohort

    Source sentences

    Summary
    Twenty-seven (27.5%) patients developed complications, of which 14 (14.2%) were major complications.
    1 context sentence
    Summary · context
    We conducted a phase II single-arm trial of a single dose of preoperative lanreotide (120 mg) in patients undergoing either pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
  4. 04HumanNon-randomized trialSafety outcome

    After preoperative lanreotide, 14 patients (14.2%) developed major complications.

    In plain wordsAfter preoperative lanreotide, 14 patients developed major complications.

    Peptide
    Lanreotide
    Outcome
    Not applicableMajor complications
    Study

    n = 98

    Outcome group
    Adverse events · Whole body
    Studied dose
    120 mg single preoperative doseAs given in this study (human).

    Measurements

    Patients with major complications
    14 patients
    overall cohort
    Patients with major complications
    14.2%
    overall cohort

    Source sentences

    Summary
    Twenty-seven (27.5%) patients developed complications, of which 14 (14.2%) were major complications.
    1 context sentence
    Summary · context
    We conducted a phase II single-arm trial of a single dose of preoperative lanreotide (120 mg) in patients undergoing either pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).
  5. 05HumanNon-randomized trialSafety outcome

    Preoperative lanreotide-related adverse events consisted of mild skin reactions in two patients (2%).

    In plain wordsTwo patients had mild skin reactions related to preoperative lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableDrug-related skin reactions
    Study

    n = 98

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    120 mg single preoperative doseAs given in this study (human).

    Measurements

    Patients with drug-related mild skin reactions
    2 patients
    overall cohort
    Patients with drug-related mild skin reactions
    2%
    overall cohort

    Source sentences

    Summary
    Drug-related adverse events were limited to mild skin reactions in two (2%) patients.
    1 context sentence
    Summary · context
    We conducted a phase II single-arm trial of a single dose of preoperative lanreotide (120 mg) in patients undergoing either pancreaticoduodenectomy (PD) or distal pancreatectomy (DP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.